WO2006037993A3 - Cancer markers - Google Patents
Cancer markers Download PDFInfo
- Publication number
- WO2006037993A3 WO2006037993A3 PCT/GB2005/003813 GB2005003813W WO2006037993A3 WO 2006037993 A3 WO2006037993 A3 WO 2006037993A3 GB 2005003813 W GB2005003813 W GB 2005003813W WO 2006037993 A3 WO2006037993 A3 WO 2006037993A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancers
- markers
- ovarian
- colorectal
- tissues
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title 1
- 230000002611 ovarian Effects 0.000 abstract 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 abstract 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 1
- 102100039282 Cytochrome P450 26A1 Human genes 0.000 abstract 1
- 102100032640 Cytochrome P450 2F1 Human genes 0.000 abstract 1
- 102100026515 Cytochrome P450 2S1 Human genes 0.000 abstract 1
- 102100026513 Cytochrome P450 2U1 Human genes 0.000 abstract 1
- 102100038696 Cytochrome P450 3A43 Human genes 0.000 abstract 1
- 102100039203 Cytochrome P450 3A7 Human genes 0.000 abstract 1
- 102100024916 Cytochrome P450 4F11 Human genes 0.000 abstract 1
- 102100022028 Cytochrome P450 4V2 Human genes 0.000 abstract 1
- 102100022027 Cytochrome P450 4X1 Human genes 0.000 abstract 1
- 102100022034 Cytochrome P450 4Z1 Human genes 0.000 abstract 1
- 101000941738 Homo sapiens Cytochrome P450 2F1 Proteins 0.000 abstract 1
- 101000855328 Homo sapiens Cytochrome P450 2S1 Proteins 0.000 abstract 1
- 101000855331 Homo sapiens Cytochrome P450 2U1 Proteins 0.000 abstract 1
- 101000957698 Homo sapiens Cytochrome P450 3A43 Proteins 0.000 abstract 1
- 101000745715 Homo sapiens Cytochrome P450 3A7 Proteins 0.000 abstract 1
- 101000909111 Homo sapiens Cytochrome P450 4F11 Proteins 0.000 abstract 1
- 101000896951 Homo sapiens Cytochrome P450 4V2 Proteins 0.000 abstract 1
- 101000896935 Homo sapiens Cytochrome P450 4Z1 Proteins 0.000 abstract 1
- 102100021695 Lanosterol 14-alpha demethylase Human genes 0.000 abstract 1
- 101710146773 Lanosterol 14-alpha demethylase Proteins 0.000 abstract 1
- 108010022037 Retinoic Acid 4-Hydroxylase Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 108010026647 cytochrome P-450 4X1 Proteins 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000000664 rectum Anatomy 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Provided are previously uncharacterised markers of cancers, for example ovarian and colorectal cancers, and uses of these as diagnostic and prognostic markers of cancers, and in particular ovarian and colorectal cancers. The markers are the cytochrome p450 enzymes: CYP51, CYP2S1, CYP2U1, CYP3A43, CYP4F11, CYP4X1, CYP4Z1, CYP26A1, CYP3A7, CYP2F1, CYP4V2, and CYP39. The invention further provides related methods and materials for the use of the markers in therapeutic intervention in ovarian, colorectal, and other cancers e.g. to specifically target neoplastic cells without causing significant toxicity in healthy tissues, and to provide methods for the evaluation of the ability of candidate therapeutic compounds to modulate the biological activity of cancerous cells from the ovary, colon, rectum, and other tissues.
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0421913.5 | 2004-10-02 | ||
| GB0421917.6 | 2004-10-02 | ||
| GB0421914.3 | 2004-10-02 | ||
| GB0421919A GB0421919D0 (en) | 2004-10-02 | 2004-10-02 | Cytochrome P450 prodrug target |
| GB0421918.4 | 2004-10-02 | ||
| GB0421920A GB0421920D0 (en) | 2004-10-02 | 2004-10-02 | Cytochrome P450 enzymes and cancer |
| GB0421913A GB0421913D0 (en) | 2004-10-02 | 2004-10-02 | Tumour-specific pro drug target |
| GB0421918A GB0421918D0 (en) | 2004-10-02 | 2004-10-02 | Cancer therapeutic target |
| GB0421920.0 | 2004-10-02 | ||
| GB0421914A GB0421914D0 (en) | 2004-10-02 | 2004-10-02 | Drug metabolising enzyme in cancer |
| GB0421919.2 | 2004-10-02 | ||
| GB0421917A GB0421917D0 (en) | 2004-10-02 | 2004-10-02 | Cancer diagnosis and therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006037993A2 WO2006037993A2 (en) | 2006-04-13 |
| WO2006037993A3 true WO2006037993A3 (en) | 2006-06-15 |
Family
ID=35530799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2005/003813 WO2006037993A2 (en) | 2004-10-02 | 2005-10-03 | Cancer markers |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006037993A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104745592A (en) * | 2013-12-31 | 2015-07-01 | 第三军医大学第一附属医院 | CYP4V2 gene mutant and application thereof |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2009114A1 (en) * | 2007-06-29 | 2008-12-31 | Bayer Schering Pharma Aktiengesellschaft | Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones |
| ES2332557B1 (en) | 2007-12-04 | 2011-02-02 | Universidad Autonoma De Madrid | GENOMIC FOOTPRINT FOR THE FORECAST OF THE EVOLUTION OF COLORECTAL ADENOCARCINOMA. |
| WO2012143380A1 (en) * | 2011-04-20 | 2012-10-26 | F. Hoffmann-La Roche Ag | Microwaves for immunohistochemical analysis |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| FI3273986T3 (en) | 2015-03-27 | 2024-02-07 | Immatics Biotechnologies Gmbh | NEW PEPTIDES AND PEPTIDE COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT CANCER |
| WO2024223797A1 (en) | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
-
2005
- 2005-10-03 WO PCT/GB2005/003813 patent/WO2006037993A2/en active Application Filing
Non-Patent Citations (4)
| Title |
|---|
| KUMARAKULASINGHAM MEERA ET AL: "Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 MAY 2005, vol. 11, no. 10, 15 May 2005 (2005-05-15), pages 3758 - 3765, XP009060128, ISSN: 1078-0432 * |
| MCKAY J A ET AL: "EXPRESSION OF CYTOCHROME P450 CYP1B1 IN BREAST CANCER", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 374, 1995, pages 270 - 272, XP000615313, ISSN: 0014-5793 * |
| MURRAY G I ET AL: "CYTOCHROME P450 EXPRESSION IS A COMMON MOLECULAR EVENT IN SOFT TISSUE SARCOMAS", JOURNAL OF PATHOLOGY, CHICHESTER, SUSSEX, GB, vol. 171, no. 1, 1 September 1993 (1993-09-01), pages 49 - 52, XP000196718, ISSN: 0022-3417 * |
| TSUNEDOMI RYOUTCHI ET AL: "Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 27, no. 3, September 2005 (2005-09-01), pages 661 - 667, XP009060122, ISSN: 1019-6439 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104745592A (en) * | 2013-12-31 | 2015-07-01 | 第三军医大学第一附属医院 | CYP4V2 gene mutant and application thereof |
| CN104745592B (en) * | 2013-12-31 | 2020-02-21 | 第三军医大学第一附属医院 | CYP4V2 Gene Mutants and Their Applications |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006037993A2 (en) | 2006-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pham-Ledard et al. | Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma | |
| WO2006047483A3 (en) | Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens | |
| WO2008028926A3 (en) | Methods and compositions for the prediction of response to trastuzumab containing chemotherapy regimen in malignant neoplasia | |
| Sharma et al. | Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease | |
| Suzuki et al. | RETRACTED: Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer | |
| Kim et al. | Genetic and clinical characteristics of phyllodes tumors of the breast | |
| WO2004065583A3 (en) | Gene expression markers for breast cancer prognosis | |
| WO2008008315A3 (en) | Compositions and methods for inhibiting growth of smad4-deficient cancers | |
| WO2006012646A3 (en) | Amacr cancer markers | |
| WO2009019368A3 (en) | Method for the assay of liver fatty acid-binding protein, ace and ca19-9 for the in vitro diagnosis of colorectal cancer | |
| WO2006133923A3 (en) | Diagnosis, prognosis and prediction of recurrence of breast cancer | |
| WO2007146668A3 (en) | Use of imp3 as a prognostic marker for cancer | |
| WO2005123993A8 (en) | Phage microarray profiling of the humoral response to disease | |
| WO2007133551A3 (en) | Method for testing drug sensitivity in solid tumors by quantifying mrna expression in thinly-sliced tumor tissue | |
| Yang et al. | Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression | |
| WO2009019370A3 (en) | Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer | |
| WO2006037993A3 (en) | Cancer markers | |
| US20090076098A1 (en) | Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones | |
| ATE331958T1 (en) | METHOD FOR DETECTING AND QUANTIFYING CIRCULATIVE TUMOR CELLS ARISING FROM SOLID TUMORS | |
| Chanida et al. | The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence | |
| WO2003083102A3 (en) | Cancer associated protein phosphatases and their uses | |
| WO2009019366A3 (en) | Aminoacylase 1 assay method for the in vitro diagnosis of colorectal cancer | |
| ES2685709T3 (en) | Predictive biomarker mediated by a CDK inhibitor useful for cancer therapy | |
| Huang et al. | BLZF1 expression is of prognostic significance in hepatocellular carcinoma | |
| Susini et al. | FGD3 gene as a new prognostic factor in breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05789155 Country of ref document: EP Kind code of ref document: A2 |